Nuvation Bio (NUVB) revenue breakdown
By product, License is the largest at 61% of fiscal 2025 revenue, growing 1721% a year over 1 years.
By region, Japan is the largest at 46% of fiscal 2025 revenue, growing 958% a year over 1 years.
Revenue by product
Fiscal years, as Nuvation Bio reports them in its 10-K filings; fiscal 2025 total $63M.
| Products | 2024 | 2025 | Share |
|---|---|---|---|
| License | $2M | $38M | 61% |
| Product Revenue | — | $25M | 39% |
| Research and development service revenue | $6M | — | — |
Revenue by region
Fiscal years, as Nuvation Bio reports them in its 10-K filings; fiscal 2025 total $63M.
| Regions | 2024 | 2025 | Share |
|---|---|---|---|
| Japan | $3M | $29M | 46% |
| UNITED STATES | — | $25M | 39% |
| China | $5M | $9M | 15% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for NUVB.
Open NUVB in InvestinglyQuestions
Where does Nuvation Bio make its money?
In fiscal 2025, by product: License $38M, Product Revenue $25M.
From Nuvation Bio's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.